(19)
(11) EP 1 565 239 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
22.06.2011 Bulletin 2011/25

(45) Mention of the grant of the patent:
16.03.2011 Bulletin 2011/11

(21) Application number: 03811379.1

(22) Date of filing: 17.11.2003
(51) International Patent Classification (IPC): 
A61P 9/06(2006.01)
 A61K 31/439(2006.01)
(86) International application number:
PCT/EP2003/012844
(87) International publication number:
WO 2004/045591 (03.06.2004 Gazette 2004/23)

(54)

LIQUID PHARMACEUTICAL FORMULATIONS CONTAINING 3,7-DIAZABICYCLO[3,3,1] NONANES FOR TREATING ANTI-ARRHYTHMIC EVENTS

FLÜSSIGE ZUSAMMENSETZUNGEN MIT 3,7-DIAZABICYCLO[3,3,1] NONANEN ZUR BEHANDLUNG VON ANTI-ARRHYTHMISCHEN EREIGNISSEN

PREPARATIONS PAHRMACEUTIQUES LIQUIDES CONTENANT DES COMPOSES 3,7-DIAZABICYCLO[3,3,1] NONANE ET METHODE DE TRAITEMENT DE MANIFESTATIONS ANTI-ARYTHMIQUES

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

(30) Priority: 18.11.2002 US 426795 P

(43) Date of publication of application:
24.08.2005 Bulletin 2005/34

(73) Proprietor: Abbott Products GmbH
30173 Hannover (DE)

(72) Inventors:
  • STRAUB, Matthias
    1873 JW Groet (NL)
  • JANSEN, Johannes, Wilhelmus, Catharine, Maria
    NL-4105 LE Culemborg (NL)
  • DE VRIES, Michiel, Henricus
    NL-1381 EC Weesp (NL)
  • STEINBORN, Claus, Rudolf
    30938 Burgwedel (DE)
  • CAUTREELS, Werner
    NL-1381 XA Weesp (NL)

(74) Representative: Gosmann, Martin et al
Abbott Products GmbH IP Department (PH-ZP)
Hans-Böckler-Allee 20 30173 Hannover
Hans-Böckler-Allee 20 30173 Hannover (DE)


(56) References cited: : 
EP-A- 0 550 383
 WO-A-99/31100
   
  • FISCHBACH P S ET AL: "Tedisamil in a chronic canine model of atrial flutter" JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, NEW YORK, NY, US, vol. 34, no. 2, August 1999 (1999-08), pages 212-218, XP009023056 ISSN: 0160-2446
  • BARGHEER K ET AL: "Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent." EUROPEAN HEART JOURNAL. ENGLAND OCT 1994, vol. 15, no. 10, October 1994 (1994-10), pages 1409-1414, XP008030634 ISSN: 0195-668X
  • DORIAN P ET AL: "Tedisamil increases coherence during ventricular fibrillation and decreases defibrillation energy requirements." CARDIOVASCULAR RESEARCH. NETHERLANDS FEB 1997, vol. 33, no. 2, February 1997 (1997-02), pages 485-494, XP001189258 ISSN: 0008-6363
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).